AYTU BIOPHARMA, INC — Form 10-K
Filed September 22, 2026 · analyzed by the Periodic Agent
10-K
▼ Likely negative
significance 72/100
What the filing says
Effective June 23, 2026, Aytu BioPharma and Lannett Company terminated their License and Distribution Agreement for Metadate CD (methylphenidate ER). Lannett transfers the NDA (New Drug Application 021259) back to Lannett; Aytu retains rights to sell existing inventory with royalty payments to Lannett continuing until inventory is depleted. No dollar amounts, royalty percentages, or inventory quantities are disclosed in the termination agreement.
Why this rating
Aytu loses ongoing distribution rights to approved branded product representing core asset; termination materially reduces revenue stream for $7.2M company, though inventory sell-through provides near-term transition period.
Price action (we called it negative)
before filing · preread $2.34 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.